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Q  Does vitamin D without 
calcium reduce fracture risk? 
 No. Supplemental vitamin D 
 without calcium—in doses averag-
ing as much as 800 IU per day—doesn’t 
reduce the risk of hip, vertebral, or non-
vertebral fractures in postmenopausal 
women and older men (strength of recom-
mendation [SOR]: A, large, high-quality 
meta-analysis of randomized or quasi- 
randomized placebo-controlled trials). 
The vitamin D analogs alfacalcidol and 
calcitriol also don’t reduce hip or nonver-
tebral fractures (SOR: A, multiple random-
ized, controlled trials [RCTs]), although 
alfacalcidol (but not calcitriol) does reduce 
vertebral fractures by 43% (SOR: B, one 
RCT and one quasi-randomized trial with 
potential for bias)
Vitamin D supplementation, with or 
without calcium, doesn’t affect mortality. 
It does double the risk of mild hypercal-
cemia (about 2.7 mmol/L increase), raise 
the risk of renal calculi or mild renal insuf-
ficiency by 16%, and slightly increase (4%) 
gastrointestinal adverse effects (SOR: A, 
meta-analysis of RCTs or quasi-random-
ized trials).
Evidence summary
A 2014 meta-analysis of 15 trials (quasi-
random and RCT) with a total of 28,271 pa-
tients that compared the effect of vitamin D 
on fracture risk with placebo or no treatment, 
found no benefit for vitamin D supplemen-
tation (TABLE).1 Patients lived in community 
and nursing home settings and ranged in age 
from 50 to 85 years; 24% to 100% were female. 
Only 3 trials required patients to have 
had a previous fracture. Exclusions included: 
diseases affecting bone metabolism, cogni-
tive impairment, drugs affecting bone metab-
olism (bisphosphonates, selective estrogen 
receptor modulators, and corticosteroids), 
renal failure, hypercalcemia, nephrolithiasis, 
and decreased mobility (recent stroke recov-
ery and Parkinson’s disease). 
Formulations of vitamin D included cho-
lecalciferol (D3) 400 to 2000 IU/d for 4 months 
to 5 years or 100,000 to 500,000 IU every 3 to 
12 months for 1 to 5 years; calcifediol (25(OH)
D3) 600 IU/d for 4 years; and ergocalciferol 
(D2) 400 IU/d for 2 years or 3000 to 300,000 IU 
every 3 to 12 months for 10 months to 3 years.
Vitamin D analogs  
generally have no benefit either
The same meta-analysis compared vitamin D 
analogs to placebo or no treatment (8 trials, 
quasi-random and RCT, 1743 patients) on the 
risk of fracture, again finding no benefit in all 
but one case. Included patients were mostly 
by referral to tertiary or university hospitals 
and outpatient community settings. 
Most of the studies included only a small 
number of patients (about 200), with the larg-
est study having 740 patients. The age range 
was 50 to 77 years, and 50% to 100% were fe-
male. Most of the trials required patients to 
have osteoporosis or vitamin D deficiency 
with a previous vertebral deformity on 
imaging. Study exclusions included osteoma-
lacia, malabsorption, hyperparathyroidism, 
active kidney stones, history of hypercalci-
uria, cancer, incurable disease, dementia, 
severe chronic illness (renal or liver failure), 
recent stroke or fracture, and drugs that affect 
bone metabolism.
Vitamin D analogs were given as 
alfacalcidol (1-alphahydroxyvitamin D3) 
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0.5 mcg twice daily or 1 mcg/d for 36 weeks 
to 2 years or calcitriol (1,25-dihydroxyvitamin 
D3) 0.25 to 1 mcg once or twice daily for one 
to 3 years. Researchers found a significant 
reduction in vertebral (but not nonvertebral 
or hip) fractures with alfacalcidol, but the 
finding occurred in a single trial that was 
assessed by the authors of the meta-analysis 
as subject to bias.
Supplementation doesn’t affect  
mortality, but does have some side effects
Patients taking vitamin D or an analog with 
or without calcium showed no difference in 
risk of death compared with patients taking 
placebo (29 trials, 71,032 patients; relative 
risk [RR]=0.97; 95% confidence interval [CI], 
0.93-1.01). 
Patients taking vitamin D or an analog 
were more likely than controls to have mild 
hypercalcemia, with an average increase 
of 2.7 mmol/L (21 trials, 17,124 patients; 
RR=2.28; 95% CI, 1.57-3.31). Patients tak-
ing calcitriol had the highest risk (4 trials, 
988 patients; RR=4.41; 95% CI, 2.14-9.09). 
Gastrointestinal adverse effects (4% 
increase) and renal calculi or mild renal 
insufficiency (16% increase) were more 
common with vitamin D and analogs than 
placebo (GI adverse effects: 15 trials, 47,761 
patients; RR=1.04; 95% CI, 1.00-1.08; renal 
calculi or mild renal insufficiency: 11 trials, 
46,548 patients; RR=1.16; 95% CI, 1.02-1.33). 
Recommendations 
There are no guidelines recommending vita-
min D supplementation without calcium to 
prevent fracture.                   JFP
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TABLE
How vitamin D and vitamin D analog supplementation 
affects fracture risk compared with placebo or no treatment1
Supplement Number of trials (total 
patients)
Outcome Fracture RR 95% CI Comments
Vitamin D 12 (22,930) Nonvertebral 
fracture
1.05 0.96-1.14 Nonsignificant
11 (27,693) Hip fracture 1.12 0.98-1.29 Nonsignificant
  6 (11,396) Vertebral fracture 
or deformity
1.03 0.76-1.39 Nonsignificant
15 (28,271) Any new fracture 1.03 0.96-1.11 Nonsignificant
Alfacalcidol   4 (658) Nonvertebral 
fracture
0.70 0.22-2.18 Nonsignificant
  1 (132) Hip fracture 0.33 0.01-8.04 Nonsignificant
  2 (872) Vertebral fracture 0.57 0.49-0.65 Significant*
Calcitriol   1 (246)  Nonvertebral 
fracture
0.42 0.15-1.15 Nonsignificant
  1 (246) Hip fracture 0.33 0.01-8.10 Nonsignificant
  3 (327) New vertebral 
fracture or  
deformity
0.75 0.40-1.41 Nonsignificant
CI, confidence interval; RR, relative risk.
*Result subject to bias.
